

## This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	<i>Mdm2 p53 binding protein homolog (MDM2; HDM2)</i>	Human genotyping studies suggest that an <i>MDM2</i> mutation could help predict disease severity in retinoblastoma patients. Genotyping of 212 individuals carrying <i>retinoblastoma 1 (RB1)</i> mutations that cause retinoblastoma and 114 healthy controls showed that the <i>MDM2</i> SNP rs2279744 correlated with disease severity ( $p=0.001$ ). Ongoing work includes investigating other genetic factors involved in retinoblastoma development.  <i>SciBX</i> 3(45); doi:10.1038/scibx.2010.1350 Published online Nov. 18, 2010	Unpatented; available for partnering	Castéra, L. <i>et al.</i> <i>J. Natl. Cancer Inst.</i> ; published online Nov. 4, 2010; doi:10.1093/jnci/djq416 <b>Contact:</b> Claude Houdayer, Curie Institute, Paris, France e-mail: <a href="mailto:claud.houdayer@curie.net">claud.houdayer@curie.net</a>